Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

NCT03127215 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

102

Enrollment

OTHER

Sponsor class

Conditions

Cancers With DNA Repair-Deficiency

Interventions

DRUG: Olaparib
DRUG: Physician's choice
DRUG: Trabectedin

Sponsor

National Center for Tumor Diseases, Heidelberg

Collaborators

[object Object]
[object Object]
[object Object]